

# Lars Hangartner

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3911221/publications.pdf>

Version: 2024-02-01

35  
papers

4,387  
citations

304368

22  
h-index

395343

33  
g-index

41  
all docs

41  
docs citations

41  
times ranked

5493  
citing authors

#	ARTICLE	IF	CITATIONS
1	Internalization of HIV-1 by Phagocytes Is Increased When Virions Are Opsonized with Multimeric Antibody in the Presence of Complement. <i>Journal of Virology</i> , 2022, 96, JVI0168921.	1.5	0
2	Accelerated Clearance and Degradation of Cell-Free HIV by Neutralizing Antibodies Occurs via Fc $\gamma$ RIIb on Liver Sinusoidal Endothelial Cells by Endocytosis. <i>Journal of Immunology</i> , 2021, 206, 1284-1296.	0.4	6
3	Effector function does not contribute to protection from virus challenge by a highly potent HIV broadly neutralizing antibody in nonhuman primates. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	23
4	Enhanced Ability of Plant-Derived PGT121 Glycovariants To Eliminate HIV-1-Infected Cells. <i>Journal of Virology</i> , 2021, 95, e0079621.	1.5	6
5	Passive Transfer of Vaccine-Elicited Antibodies Protects against SIV in Rhesus Macaques. <i>Cell</i> , 2020, 183, 185-196.e14.	13.5	25
6	Broadly Neutralizing Antibodies to Highly Antigenically Variable Viruses as Templates for Vaccine Design. <i>Current Topics in Microbiology and Immunology</i> , 2020, 428, 31-87.	0.7	0
7	Mapping Polyclonal Antibody Responses in Non-human Primates Vaccinated with HIV Env Trimer Subunit Vaccines. <i>Cell Reports</i> , 2020, 30, 3755-3765.e7.	2.9	81
8	Public Endowment of B Cells. <i>Immunity</i> , 2019, 51, 601-603.	6.6	0
9	Vaccine-Induced Protection from Homologous Tier 2 SHIV Challenge in Nonhuman Primates Depends on Serum-Neutralizing Antibody Titers. <i>Immunity</i> , 2019, 50, 241-252.e6.	6.6	153
10	Reprogramming the antigen specificity of B cells using genome-editing technologies. <i>ELife</i> , 2019, 8, .	2.8	69
11	Glycosylation of Human IgA Directly Inhibits Influenza A and Other Sialic-Acid-Binding Viruses. <i>Cell Reports</i> , 2018, 23, 90-99.	2.9	80
12	Electron-Microscopy-Based Epitope Mapping Defines Specificities of Polyclonal Antibodies Elicited during HIV-1 BG505 Envelope Trimer Immunization. <i>Immunity</i> , 2018, 49, 288-300.e8.	6.6	175
13	Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design. <i>Annual Review of Immunology</i> , 2016, 34, 635-659.	9.5	500
14	The impact of vaccination on the breadth and magnitude of the antibody response to influenza A viruses in HIV-infected individuals. <i>Aids</i> , 2015, 29, 1803-1810.	1.0	8
15	Heterosubtypic Antibodies to Influenza A Virus Have Limited Activity against Cell-Bound Virus but Are Not Impaired by Strain-Specific Serum Antibodies. <i>Journal of Virology</i> , 2015, 89, 3136-3144.	1.5	23
16	Prevalence and Predictors for Homo- and Heterosubtypic Antibodies Against Influenza A Virus. <i>Clinical Infectious Diseases</i> , 2014, 59, 1386-1393.	2.9	9
17	Alternative Recognition of the Conserved Stem Epitope in Influenza A Virus Hemagglutinin by a V<sub>H</sub>-3-30-Encoded Heterosubtypic Antibody. <i>Journal of Virology</i> , 2014, 88, 7083-7092.	1.5	62
18	Recombinant HIV Envelope Proteins Fail to Engage Germline Versions of Anti-CD4bs bNAbs. <i>PLoS Pathogens</i> , 2013, 9, e1003106.	2.1	172

#	ARTICLE	IF	CITATIONS
19	Anti-HIV B Cell Lines as Candidate Vaccine Biosensors. <i>Journal of Immunology</i> , 2012, 189, 4816-4824.	0.4	57
20	Engineered mice and B cell lines expressing broadly neutralizing antibodies and their unmutated precursors: tools for HIV vaccinology. <i>Retrovirology</i> , 2012, 9, .	0.9	1
21	Broadly Neutralizing Human Anti-HIV Antibody 2G12 Is Effective in Protection against Mucosal SHIV Challenge Even at Low Serum Neutralizing Titers. <i>PLoS Pathogens</i> , 2009, 5, e1000433.	2.1	475
22	Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. <i>Nature Medicine</i> , 2009, 15, 951-954.	15.2	509
23	Recombination of Retrotransposon and Exogenous RNA Virus Results in Nonretroviral cDNA Integration. <i>Science</i> , 2009, 323, 393-396.	6.0	131
24	Antibodies against viruses: passive and active immunization. <i>Current Opinion in Immunology</i> , 2008, 20, 486-492.	2.4	41
25	Absence of CTL Responses to Early Viral Antigens Facilitates Viral Persistence. <i>Journal of Immunology</i> , 2008, 180, 3113-3121.	0.4	22
26	Attenuated measles virus as a vaccine vector. <i>Vaccine</i> , 2007, 25, 2974-2983.	1.7	74
27	Extralymphatic virus sanctuaries as a consequence of potent T-cell activation. <i>Nature Medicine</i> , 2007, 13, 1316-1323.	15.2	54
28	Fc receptor but not complement binding is important in antibody protection against HIV. <i>Nature</i> , 2007, 449, 101-104.	13.7	828
29	Natural IgE Production in the Absence of MHC Class II Cognate Help. <i>Immunity</i> , 2006, 24, 329-339.	6.6	103
30	Antiviral antibody responses: the two extremes of a wide spectrum. <i>Nature Reviews Immunology</i> , 2006, 6, 231-243.	10.6	275
31	Parameters governing exhaustion of rare T cell-independent neutralizing IgM-producing B cells after LCMV infection. <i>European Journal of Immunology</i> , 2006, 36, 3175-3185.	1.6	15
32	Nonneutralizing antibodies binding to the surface glycoprotein of lymphocytic choriomeningitis virus reduce early virus spread. <i>Journal of Experimental Medicine</i> , 2006, 203, 2033-2042.	4.2	49
33	Deliberate removal of T cell help improves virus-neutralizing antibody production. <i>Nature Immunology</i> , 2004, 5, 934-942.	7.0	85
34	Antiviral immune responses in gene-targeted mice expressing the immunoglobulin heavy chain of virus-neutralizing antibodies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 12883-12888.	3.3	59
35	Observation of Measles Virus Cell-to-Cell Spread in Astrocytoma Cells by Using a Green Fluorescent Protein-Expressing Recombinant Virus. <i>Journal of Virology</i> , 1999, 73, 9568-9575.	1.5	183